Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers

NCT01647867 | Completed

• 2 other identifiers: MetLung - 12042012-A00468-35
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 2

Brief Summary

Our project, established through collaboration between clinicians (Oscar Lambret Center-University Hospital) and scientists (IBL), aims to evaluate the expression of Met fragments in the lung cancer (LC). Unlike previous studies on Met by sequencing, in situ hybridization or immunohistochemistry, the investigators propose a protein analysis by Western blot of tumor samples and healthy tissue. This approach will evaluate the expression of full-length receptor, the potential presence of intracellular fragments, and their phosphorylation status.

Conditions

Non Small Cell Lung Cancer

Keywords

Met fragments expression

Outcome Measures

Primary Outcomes (1)

• Expression and localization of Met C-terminal active fragments in NSCLC

  Western Blot and immunohistochemistry

  baseline

Secondary Outcomes (3)

• Evaluation of the activation of Met receptor

  baseline

• Correlation between expression of Met receptor fragments with clinical characteristics and/or prognosis factors as sex, TNM, EGFR status, histology, smoking status, survival

  baseline

• Expression in plasma of N-terminal Met fragments

  baseline

Study Arms (1)

Met analysis

EXPERIMENTAL

Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test

Other: Met analysis on tissue and blood

Interventions

Met analysis on tissue and blood OTHER

10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease

Met analysis

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with non small cell lung cancer (NSCLC)
• Patients candidate for bronchial biopsies at the Oscar Lambret Center (metastatic stage) or candidate for thoracic surgery at University Hospital of Lille (localized stage)
• Treatment naive patient for metastatic NSCLC
• Patients with or without neoadjuvant therapy for localized NSCLC
• Male or female patients aged ≥ 18 years
• Patient registered with the social security system
• Having signed a written Informed Consent

You may not qualify if:

• Malignant tumors which are not carcinoma
• Small-cell malignant tumors
• Secondary bronchial lesions
• Revision surgery
• Pregnant or breastfeeding women
• Patient under guardianship or tutorship
• Previous cancer

Sponsors & Collaborators

• Centre Oscar Lambret: lead

Study Sites (2)

Centre Hospitalier Régional et Universitaire

Lille, 59 037, France

Location

Oscar Lambret Center

Lille, 59020, France

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Eric DANSIN, MD

  Centre Oscar Lambret

  STUDY DIRECTOR

• David TULASNE, PhD

  Institute of Biology of Lille

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 17, 2012
• First Posted: July 24, 2012
• Study Start: August 27, 2012
• Primary Completion: July 1, 2015
• Study Completion: July 1, 2016
• Last Updated: March 13, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

FR (2)